Certification critical to broad U.S. market release of the CNSide CSF Assay Platform CNSide now meets key federal and state regulatory requirements, including those set by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Lab Improvement Amendments (CLIA) HOUSTON, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted rad ...

Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD)Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Terese C. Hammond, MD as Head of Inflammatory and Pulmonary Diseases, effective immediately. Dr. Hammond is a nationally recognized leader ...

Accessibility StatementSkip Navigation RESTON, Va., Sept. 18, 2025 /PRNewswire/ -- V2X Inc., (NYSE: VVX), has been awarded a position on the Defense Threat Reduction Agency's (DTRA) Cooperative Threat Reduction Integrating Contract IV (CTRIC IV). V2X is one of six recipients selected for this indefinite-deliver, indefinite-quantity contract, which carries a ceiling value of $3.5 billion over a five-year base period with five additional option years. CTRIC IV supports the Department of Defense's global Coope ...

ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH) today announced the closing of its refinanced first lien credit facility. The refinanced credit facility provides for the refinancing of the $886.0 million principal balance of existing first lien term loans, the additional borrowing of $439.0 million in incremental first lien term loans, and the upsize of its revolving credit facility from $170.3 million of maximum availability to $250.0 million of maxim ...

AVITA Medical, Inc. (NASDAQ: RCEL ) is a company working on a complete portfolio for full-thickness wound reconstruction. They offer RECELL and RECELL GO for point-of-care autologous “Spray-On Skin.” RCEL also has Cohealyx for graft-ready dermis, and PermeaDerm as a protective biosynthetic cover in partnershipMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from ...

FREMONT, CA / ACCESS Newswire / September 18, 2025 / Aehr Test Systems (NASDAQ:AEHR), a worldwide supplier of semiconductor test and burn-in equipment, today announced that President and CEO Gayn Erickson will be participating in the 17th Annual CEO Investor Summit 2025 being held Tuesday, October 7that The Arrogant Butcher restaurant in Phoenix, Arizona. "I once again look forward to engaging with investors and shareholders to discuss Aehr's innovative wafer-level test and packaged part burn-in solutions t ...

Second acquisition under Digital Asset Treasury strategy positions Caliber alongside Chainlink’s infrastructure-first vision and marks the beginning of a growing LINK treasurySCOTTSDALE, Ariz., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Caliber (NASDAQ: CWD), a diversified real estate and digital asset management platform, today announced it has completed a $6.5 million purchase of Chainlink (LINK) tokens as part of its Digital Asset Treasury (DAT) Strategy. The Company acquired 278,011 LINK tokens at an average ac ...

Regulatory Milestone Underscores Continued Promise of First-in-Class Mitochondrial Cell TherapyHAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the Company’s lead investigational compound, MNV-201 for Myelodysplastic Syndr ...

JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that its wholly owned subsidiary, Edge Autonomy, has been awarded a contract from an undisclosed European NATO country to deliver its Edge Autonomy Stalker Group 2 fixed wing uncrewed aerial system (UAS) to perform long-range reconnaissance and intelligence gathering. The contract includes Stalker aircraft systems, spares package, and training. By addr. ...

Accessibility StatementSkip Navigation NEW HAVEN, Conn., Sept. 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical- stage biopharmaceutical company developing the investigational therapy Haduvioâ"¢ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that data from the Phase 2a RIVER trial of nalbuphine ER for the treatment ...